Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- PMDA to Kick Off Pilot Program for Electronic Filings of NDA Data in October
October 16, 2013
- Japan “Hopes to Find Common Ground” in Upcoming TPP Talks on Intellectual Properties: Minister Amari
October 16, 2013
- Generic-Name Prescribing Promoted Use of Generic Drugs in FY2012: CSIMC Committee
October 11, 2013
- CSIMC Pricing Subcommittee to Explore “Responses” to Diovan Uproar
October 10, 2013
- Expert Group Calls for Handling of Switch OTC Drugs as Careful as Ethical Drugs in Early Stage after Switching
October 10, 2013
- Working Group Finalizes Recommendation on Rules for Online Sales of OTC Drugs
October 10, 2013
- MHLW Formally Compiles Interim Report of Expert Panel on Diovan Scandal
October 10, 2013
- Applications Based on Information in Public Domain Appropriate for 4 Drugs Including Vancomycin: Council on Unapproved Drugs
October 9, 2013
- Nonpartisan Lawmaker Group to Hold Study Session on Diovan Scandal
October 8, 2013
- Council on Regulatory Reform to Begin Holding Open Public Discussions Later This Year
October 8, 2013
- Addition of TACE Use for Farmorubicin to Be Reported to PAFSC Second Committee
October 7, 2013
- NIBIO to Strengthen Academia’s Drug Discovery Support Initiatives in Order to Evaluate 400 Research Themes by FY2015
October 4, 2013
- PMDA Considers Offering Development Strategy Consultations to Drug Makers: Office Director
October 3, 2013
- Industrial Competitiveness Council Finalizes Enforcement Policy for New Growth Strategy; Recommends Name for Japanese Version of NIH
October 3, 2013
- PMDA Branch in Kansai Region Officially Opens
October 2, 2013
- Interim Report of Diovan Panel Fails to Lay Bare Who Altered Data, for What Purpose
October 1, 2013
- MHLW to Strengthen Measures Against Improper Research Practices from FY2014; Surprise Inspections Also Planned
October 1, 2013
- Health Ministry Approves Sovriad, Hizentra
September 30, 2013
- Incentives to Promote the Use of Generic Drugs by DPC Hospitals Being Discussed: Director Utsunomiya of MED
September 30, 2013
- TPP Partners Likely to Accept Japanese Proposal on Data Exclusivity Period: Mr Eto of LDP
September 30, 2013
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…